AbbVie Says Canada's Drug Agency Recommends ELAHERE Be Reimbursed With Conditions For Treatment Of Certain Types Of Platinum-Resistant Ovarian Cancers

Author: Benzinga Newsdesk | October 30, 2025 06:31am

• ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC)
• ELAHERE® was submitted for reimbursement review 180 days prior to Health Canada's approval in line with CDA-AMC's new Target Zero initiative

MONTREAL, Oct. 30, 2025 /CNW/ - Today, AbbVie (NYSE:ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

As part of CDA-AMC's Target Zero initiative—designed to accelerate patient access to promising new treatments by removing delays between Health Canada approval and CDA-AMC's reimbursement recommendation to participating public drug plans—ELAHERE® was submitted for reimbursement review 180 days prior to Health Canada's approval, which has resulted in a positive reimbursement recommendation for patients living with certain types of platinum-resistant ovarian cancer, a disease with the lowest survival rate among gynecological cancers in Canada.4 The Target Zero initiative represents a meaningful step towards faster access to innovative new treatment options.

Posted In: ABBV